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MicroRNA-155 (miR-155) has emerged as a critical regulator of
immune cell development, function, and disease. However, the
mechanistic basis for its impact on the hematopoietic system
remains largely unresolved. Because miRNAs function by repress-
ing specific mRNAs through direct 3UTR interactions, we have
searched for targets of miR-155 implicated in the regulation of
hematopoiesis. In the present study, we identify Src homology-2
domain-containing inositol 5-phosphatase 1 (SHIP1) as a direct
target of miR-155, and, using gain and loss of function approaches,
show that miR-155 represses SHIP1 through direct 3UTR interac-
tions that have been highly conserved throughout evolution.
Repression of endogenous SHIP1 by miR-155 occurred following
sustained over-expression of miR-155 in hematopoietic cells both
in vitro and in vivo, and resulted in increased activation of the
kinase Akt during the cellular response to LPS. Furthermore, SHIP1
was also repressed by physiologically regulated miR-155, which
was observed in LPS-treated WT versus miR-155/ primary mac-
rophages. In mice, specific knockdown of SHIP1 in the hematopoi-
etic system following retroviral delivery of a miR-155-formatted
siRNA against SHIP1 resulted in a myeloproliferative disorder, with
striking similarities to that observed in miR-155-expressing mice.
Our study unveils a molecular link between miR-155 and SHIP1 and
provides evidence that repression of SHIP1 is an important com-
ponent of miR-155 biology.
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In recent years, microRNAs have emerged as critical regulatorsof gene expression in a variety of mammalian cell types,
including cells of the immune system (1–3). Through their ability
to repress expression of specific target genes via direct 3UTR
interactions, several miRNAs have been shown to impact both
physiological and pathological immune processes (4–12).
Among the most prominent and well-studied immune system
miRNAs to date, microRNA-155 (miR-155) clearly is involved in
protective immunity when properly regulated, yet contributes to
malignant conditions upon its dysregulated expression.
MiRNA-155 is expressed in a variety of immune cell types,
including B cells (8, 9, 13–17), T cells (18), macrophages (19, 20),
dendritic cells (8), and progenitor/stem cell populations (7, 21).
Interestingly, miR-155 is found at low levels in most of these cells
types until their activation by immune stimuli, such as antigen,
Toll-like Receptor ligands, and inflammatory cytokines, which
rapidly increase miR-155 expression (8, 9, 18–20). Consistent
with its expression pattern, miR-155 appears to function in
hematopoiesis and the immune response (7–9). For example,
defective germinal center formation and antibody isotype class-
switching have been observed in miR-155/ mice following
infection or vaccination (8, 9, 22). In T cells, miR-155 promotes
skewing toward the Th1 subset (8, 9). In dendritic cells, miR-155
is necessary for proper activation of responder T cells in the
context of antigen presentation (8).
Enhanced expression of miR-155 occurs constitutively in a
subset of cancer cells of lymphoid (13–17) and myeloid origin (7,
23). We and others have recently demonstrated that sustained
expression of miR-155 in the hematopoietic system leads to
pathological outcomes. Our group expressed miR-155 ubiqui-
tously in the hematopoietic compartment via bone marrow
transfer of hematopoietic stem cells (HSCs) infected with a
retroviral vector. This caused a myeloproliferative disorder
(MPD) characterized by increased granulocyte/monocyte (GM)
populations in the bone marrow, peripheral blood, and spleen,
impaired erythropoiesis, and severe splenomegaly because of
extramedullary hematopoiesis (7). Costinean et al. found that
transgenic expression of miR-155 from a B-cell specific pro-
moter can trigger a B-cell malignancy (4).
While much has been learned about miR-155-expression
patterns and functions, the molecular basis underlying its biology
is relatively uncharacterized. As a result, we have been searching
for candidate targets of miR-155 implicated in overlapping
biological processes. Using microarray technology, bioinformat-
ics, and an extensive review of the literature, we have identified
the inositol phosphatase SHIP1 as a target of miR-155. Through
both gain and loss of function approaches, we demonstrate that
miR-155 represses SHIP1 through direct 3UTR interactions
during both sustained and physiological expression of miR-155.
Furthermore, specific knockdown of SHIP1 in the hematopoietic
system using a miR-155-formatted siRNA against SHIP1 largely
recapitulated the MPD phenotype we previously described in
miR-155-expressing mice. Together, our data demonstrate a
molecular link between miR-155 and SHIP1 in the immune
system, and suggest that repression of SHIP1 is a critical aspect
of miR-155 function.
Results
MicroRNA-155 Represses SHIP1 Through 3UTR Interactions. We pre-
viously performed a mRNA microarray analysis using RAW
264.7 macrophages stably expressing miR-155 to identify possi-
ble targets of miR-155 (7). Among the targets was SHIP1
(INPP5D), a gene that is repressed by miR-155 and which has a
conserved 8-mer target ‘‘seed’’ in its 3UTR (Fig. 1A). SHIP1
was of particular interest because miR-155 is the only miRNA
with a highly conserved binding site located in the SHIP1 3UTR
according to the TargetScan algorithm (24), and because mice
deficient in SHIP1 suffer from a myeloproliferative condition
resembling that which we previously described for mice express-
ing miR-155 (7, 25–28).
To directly test whether miR-155 can repress SHIP1 through
direct 3UTR interactions, we cloned the 3UTR of SHIP1 into
a reporter plasmid downstream from luciferase and performed
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reporter assays using 293 T cells. While miR-155 produced from
a cotransfected plasmid repressed expression of luciferase fused
to the WT SHIP1 3UTR, it failed to repress the SHIP1 3UTR
containing a mutated miR-155 seed sequence (Fig. 1B). As
controls, miR-155 repressed the Picalm 3UTR and 2-mer
control constructs, but not the control UTR without miR-155
sites (see Fig. 1B). These data reveal that miR-155 directly
targets the SHIP1 3UTR leading to repressed expression.
To determine whether miR-155 can repress endogenous
SHIP1, we assayed SHIP1 expression in RAW 264.7 cells
expressing WT human miR155, human miR-155 containing a
mutated seed region, or vector control. SHIP1 was measured at
the mRNA and protein levels by quantitative PCR (qPCR) and
Western blotting, respectively. WT miR-155 repressed SHIP1
mRNA and protein below control levels, while the miR-155 seed
mutant had little impact on SHIP1 expression compared with the
vector control (Fig. 1 C and D). The WT miR-155 was over-
expressed in cells receiving theWTmiR-155 vector (Fig. 1E) and
the mature miR-155 seed mutant was produced in cells receiving
the miR-155 seed-mutant vector (Fig. 1F), indicating that the
specificity of the repression was determined by the seed region
of miR-155.
SHIP1 is well known to be a negative regulator of the kinase
Akt, a downstream target of the phosphatidylinositol-3-kinase
(PI3K) pathway. Therefore, we assayed Akt activation following
LPS treatment of the different RAW 264.7 derivatives. Consis-
tent with reduced SHIP1 levels, cells expressing WT human
miR-155 exhibited increased activation of Akt following LPS
treatment, while Akt activation was similar in the control and
human miR-155 seed mutant-expressing cells (Fig. 1G).
Enhanced Expression of SHIP1 in miR-155/ Macrophages Following
LPS Treatment.We next evaluated whether SHIP1 is regulated by
miR-155 under physiological conditions. To achieve this, we
generated bone marrow-derived macrophages (BMMs) from
either WT or miR-155/ mice. As LPS has been shown to be a
potent inducer of miR-155 in macrophages (19), we stimulated
these cells with LPS over a time course. In WT cells, rapid
induction of the miR-155 precursor, BIC, was followed shortly
after by elevated expression of mature miR-155 (Fig. 2 A and B),
as previously seen with poly (I:C)-treated BMMs (19). We also
noticed that while BIC levels fall considerably by 24 h, miR-155
expression peaks at this time point. Protein levels of SHIP1 were
assayed at 0 h, 4 h, and 24 h after LPS treatment of both WT and
miR-155/ BMMs. We observed no change in SHIP1 protein
levels up to 4 h following LPS treatment in cells of both
genotypes (Fig. 2C). After 24 h, both WT and miR-155/
BMMs demonstrated an increase in SHIP1 expression as com-
pared with earlier time points. However, miR-155/BMMs had
an enhanced level of SHIP1 protein compared to WT control
Fig. 1. MicroRNA-155 represses SHIP1 expression through 3UTR interactions. (A) Schematic layout of the SHIP1 mRNA coding sequence (CDS) and 3UTR, with
the relative locationof themiR-155binding site.Depiction is not to scale. SequenceofmouseandhumanmiR-155andpredicted interactionwith conserved8-mer
miR-155 seeds found within the SHIP1 3UTRs from different species (highlighted) are shown. The sequence of the SHIP1 3UTR seed mutant used for reporter
assays andpredicted disruption of themiR-155 interaction is also shown. (B) Luciferase reporter assayswere performedby transiently transfecting 293T cellswith
an empty plasmid (FUW) or miR-155-expressing plasmid (FUW-155), the indicated 3UTR luciferase reporter plasmids, and a plasmid producing -galactosidase.
Luciferase values have been normalized to -galactosidase, and the percent of luciferase activity in cells transfected with miR-155 is presented. Raw 264.7 cells
stably infectedwith a retroviral vector expressingWThumanmiR-155 (MGP-h155), mutant seed humanmiR-155 (MGP-h155mut), or control (MGP)were assayed
for SHIP1 levels by qPCR (C) andWestern blotting (D). As a loading control for theWestern blot, -Tubulin was also assayed. The fold-repression of SHIP1 by the
different constructs is shown. (E) Levels of mature human miR-155 in the different cell types were assayed by qPCR with primers that detect the WT mature
miR-155 sequence. (F) RNA from the different cell types and a probe specific for the human miR-155 seed mutant sequence was used for Northern blotting. (G)
The different cell typeswere stimulatedwith LPS (200 ng/ml) over the indicated time course and Ser-473-phosphorylated-Akt (p-Akt), total Akt, and-Actinwere
assayed by Western blotting. Data represent at least 2 independent experiments.
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cells at this time point (see Fig. 2C). SHIP1 mRNA levels
reflected similar differences between WT and miR-155/
BMMs following 24 h of LPS treatment (Fig. 2D). These results
are consistent with miR-155 repressing SHIP1 expression after
their induced coexpression by LPS, and demonstrate that this
can occur under physiologically relevant conditions in primary
cells.
Knockdown of SHIP1 in Vivo Using siRNA in the Context of miR-155
Processing. Having identified SHIP1 as a direct target of miR-
155, we next determined if specific knockdown of SHIP1 levels
could recapitulate the miR-155 MPD phenotype in mice that we
recently described (7). Although this phenotype is predicted by
the MPD observed in SHIP1/ mice (26–28), we wanted to
perform a specific reduction in SHIP1 using the same retroviral
vector and bone marrow-reconstitution context as we used to
promote sustained miR-155 expression in the hematopoietic
system. To accomplish this, we built a retroviral vector that
expresses a miR-155 formatted SHIP1 siRNA cassette (Fig. 3A).
The cassette is driven by a RNA Polymerase II promoter and the
hairpin arms and loop are comprised of mouse miR-155 se-
quences, while the stem structure contains an antisense sequence
designed to target the SHIP1 coding sequence (see Fig. 3A).
Knockdown of other genes in vitro has been shown using this
approach (29). Following construction of this vector, we stably
infected RAW 264.7 cells and assayed SHIP1 expression. SHIP1
protein levels were markedly reduced in cells expressing the
siRNA cassette, compared to the control vector (Fig. 3B).
We next tested whether we could achieve knockdown of
SHIP1 expression in vivo by expressing miR-155 or the siRNA
against SHIP1. To this end, HSC-enriched bone marrow cells
were infected with retroviral vectors encoding miR-155, siSHIP1
or controls and used to reconstitute lethally irradiated mice, as
we previously described for delivery of miR-155. Following 2
months of reconstitution, we analyzed SHIP1 expression in the
total bone marrow by qPCR. We observed a reduction in SHIP1
mRNA levels in mice expressing miR155 or siSHIP1 compared
to control vectors (Fig. 3C).
Knockdown of SHIP1 in the Hematopoietic Compartment Causes a
MPD Similar to that Observed in Mice Expressing miR-155. Mice
expressing miR-155, siSHIP1, or control vectors were next
studied to determine their impact on hematopoietic populations
after 2 months of reconstitution. Both miR-155 (human and
mouse sequences) and siSHIP1 caused similar MPD phenotypes
in the bone marrow and spleen compared to control vectors
(Figs. 4 and 5). Gross analysis revealed a miR-155 or siSHIP1-
dependent splenomegaly and pale coloring of the bone marrow
(see Fig. 5A and unpublished observations). Flow cytometry
detected an increase in CD11b (Mac1) myeloid populations
in the bone marrow and spleen (see Figs. 4A and 5A). The
percentage of Ter119 erythroid precursor cells was increased
in the spleen and decreased in the bone marrow, while the
percentage of B220 B cells was decreased in both the spleen
and the bone marrow (see Figs. 4A and 5A).
Histological analyses of Wright-stained bone marrow smears
confirmed the presence of pathological myeloproliferative con-
ditions in miR-155- and siSHIP1-expressing mice, characterized
by elevated numbers of GM progenitors at various stages of
development compared to controls (see Fig. 4B). There was also
a reduction in developing erythroid precursors and megakaryo-
cytes in both miR-155 and siSHIP1 mice. Of note, miR-155 mice
did exhibit a subtle increase in the number of dysplastic granu-
locytic cells compared with siSHIP1, possibly because of an
additional miR-155 target. Flow cytometry also identified that
both miR-155- and siSHIP1-expressing cells, which are GFP
positive, are responsible for the increased myeloid populations
(CD11b) in the bone marrow (see Fig. 4C).
H&E staining of fixed spleen sections from miR-155 or
siSHIP1 mice revealed expanded interfollicular regions contain-
ing developing myeloid populations, erythroid precursors, and
megakaryocytes compared to control mice (see Fig. 5B). The
normal follicular architecture of the spleen was disrupted by
Fig. 2. Enhanced expression of SHIP1 in miR-155/macrophages following
LPS treatment. Bone marrow-derived macrophages from WT or miR-155/
micewere stimulatedwith 10-ng/ml LPS from Escherichia coli for the indicated
periods of time. Expression of BIC (A) or mature miR-155 (B) was assayed by
qPCR. Expression of SHIP1 was assayed in BMMs by Western blotting (C)
and qPCR (D). -Actin was assayed as a loading control for the Western blot,
whileqPCRdatawerenormalized toL32. The fold-increase in SHIP1expression
versus the WT 0-h sample is shown. Data represent at least 2 independent
experiments.
Fig. 3. Knockdown of SHIP1 in vivo using siRNA in the context of miR-155
processing. (A) Schematic of the retroviral vector (MGP-155f) used to deliver
siRNA against SHIP1 in miR-155 format. (B) Knockdown of SHIP1 was assayed
in Raw 264.7 cells infected with MGP-siSHIP1 or control vector by Western
blotting. -Tubulin was assayed as a loading control. (C) Knockdown of SHIP1
in vivo by retroviral expression of miR-155 (MGP-155, n  4 mice) or siSHIP1
(MGP-siSHIP1, n 3 mice) in the hematopoietic compartment was assayed by
qPCR using RNA isolated from total bone marrow following 2 months of
hematopoietic reconstitution. Relative expression values have been normal-
ized to L32 mRNA. A P-value of 0.05 or less using a Student’s t test was
considered statistically significant and indicated with an asterisk.









these expanded myeloid populations in both cases. Thus, miR-
155 expression and specific SHIP1 knockdown in the hemato-
poietic system triggers marked extramedullary hematopoiesis, a
likely consequence of the dysregulated blood cell development
in the bone marrow.
Discussion
Similar to miR-155, many proteins have evolved to regulate
immune cell function and cause disease upon their dysregulated
expression. Among such proteins, the inositol phosphatase
SHIP1 is expressed in the hematopoietic system and has a broad
impact on the biology of different hematopoietic cell types (30).
SHIP1 functions at the molecular level by hydrolyzing the 5
phosphate of Phosphatidylinositol (PI)-3, 4, 5-P3 to generate
PI-3,4-P2, a process that blocks PI3K-mediated membrane lo-
calization of certain PH domain-containing signaling molecules,
such as Akt and PLC (31–33). Consequently, mice with a global
SHIP1 deficiency develop a MPD characterized by increased
GM populations, and decreased B-lymphocyte numbers. This
condition is thought to occur as a result of its role as a negative
regulator of signaling by growth factors and other immune
receptors (30, 34). Furthermore, knockout of SHIP1 in B
lymphocytes causes spontaneous germinal center formation and
antibody class-switching (30, 35, 36), while a SHIP deficiency in
T cells skews peripheral T lymphocytes toward Th1 and away
from Th2 in response to an immune challenge (37). Thus, SHIP1
impacts the same cell types that express miR-155, and plays an
opposing role in many cases. In the present study, we identify and
characterize a direct link between miR-155 and SHIP1, whereby
miR-155 can directly repress expression of SHIP1 and thereby
impede its function.
The connection between miR-155 and SHIP1 has implications
for normal immune physiology, as described above, as well as
pathological conditions, such as cancer. Our present findings
demonstrate a strong correlation between the MPDs caused by
miR-155 expression or specific knockdown of SHIP1. Both
perturbed the hematopoietic process, resulting in increased GM
cell populations, reduced lymphocyte numbers, impaired eryth-
ropoiesis, and extramedullary hematopoiesis in the spleen.
Therefore, miR-155 repression of SHIP1 may prove to be a
contributing factor to human MPDs and myeloid leukemias,
where miR-155 has been shown to be over-expressed (7, 23). Of
note, SHIP1 is mutated in some acutemyeloid leukemia patients,
where loss of function has been implicated in the oncogenic
process (38, 39). As miR-155 levels are elevated in certain B-cell
lymphomas (13–17), and because SHIP1 is a negative regulator
of B-cell activation and survival (30, 35, 36), the miR-155-SHIP1
axis should also prove to be of relevance to B-cell malignancies.
Two recent abstracts suggest that this is the case (40, 41). It is also
plausible that virally encoded orthologs of miR-155 (42–44), or
miR-155 induction by viruses such as Epstein-Barr virus (45),
can decrease SHIP1 expression en route to B-cell activation and
Fig. 4. Knockdown of SHIP1 or expression of miR-155 in the hematopoietic
compartment cause similar MPDs in the bone marrow. (A) Bone marrow was
extracted frommice expressing humanmiR-155 (MG-155, n 3 mice), mouse
miR-155 (MGP-155, n 4 mice), siSHIP1 (MGP-siSHIP1, n 3 mice), or control
vectors (MG, n 2mice orMGP, n 3mice) 2months following bonemarrow
reconstitution. Total bonemarrow cells were assayed for expression of CD11b
(Mac1), Ter119, or B220 using flow cytometry. Each dot represents an indi-
vidual mouse. A P-value of 0.05 or less using a Student’s t test was considered
statistically significant and indicated with an asterisk. (B) Bone marrow from
MGP, MGP-155, or MGP-siSHIP1 mice was smeared and Wright-stained. Pho-
tomicrographs are shown (1,000 magnification). (Scale bar, 20 m.) (C)
Representative flow cytometry plots from control, MGP-155 and siSHIP1 vec-
tor-containing mouse bone marrow analyzing GFP and CD11b expression.
Fig. 5. Knockdown of SHIP1 or expression of miR-155 in the hematopoietic
compartment causes splenomegaly and extramedullary hematopoiesis in the
spleen. (A) Spleens were extracted from mice expressing human miR-155
(MG-155, n  3 mice), mouse miR-155 (MGP-155, n  4 mice), siSHIP1 (MGP-
siSHIP1,n3mice), or control vectors (MG,n2orMGP,n3mice) 2months
following bone marrow reconstitution. Spleens were weighed and RBC-
depleted splenocytes subsequently assayed for expression of CD11b, Ter119,
or B220 by FACS. Each dot represents an individual mouse. A P-value of 0.05
or less using a Student’s t test was considered statistically significant and
indicated with an asterisk. (B) Spleens from MGP, MGP-155, or MGP-siSHIP1
mice were fixed, sectioned, and H&E stained. Photomicrographs are shown
(400 magnification). (Scale bar, 50 m.)
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transformation. Interestingly, the seed region of these orthologs
is identical to that of miR-155, while the flanking regions have
diverged dramatically from the mature mammalian miR-155
sequence. This would indicate that certain viral miRNAs have
specifically evolved to repress seed-dependent targets of miR-
155, including SHIP1.
An important question in the field is whether miRNAs
function through repression of a single or a few targets, or via
the cumulative impact of repressing large sets of targets. To
date, several putative targets of miR-155 have been predicted
through bioinformatic and proteomic approaches (46), indi-
cating that there may be great complexity underlying miR-155
function. It may be that the MPD caused by miR-155 also
involves other targets than SHIP1, but our studies show that
knockdown of SHIP1 alone can phenocopy many of the effects
of miR-155. MiR-155 has various roles in different cell types
and physiological situations and analysis of particular specific
targets, such as PU.1 (22), AID (47, 48), SOCS1 (49), and now
SHIP1, suggest that individual targets likely make significant
contributions to miR-155 function in a context-dependent
manner. For example, PU.1 is repressed by miR-155 and its
over-expression has been shown to recapitulate the Ig class-
switching defect observed in miR-155/ B cells (22). AID is
repressed by miR-155 in B lymphocytes, which has been
elegantly demonstrated via germline mutation of the miR-155
seed in the 3UTR of AID (47, 48). The AID studies also
provide evidence that miR-155 targeting of AID impacts Ig
class-switching and the rate of c-myc translocations in B
lymphocytes. SOCS1 targeting by miR-155 has just recently
been shown to impact T-regulatory cell homeostasis (49).
Similar observations have been made for specific targets of
miR-150 (11, 50), miR-223 (6), and miR-17–92 (10, 12),
suggesting a common theme of a few significant targets making
dominant contributions to miRNA function. Ultimately, germ-
line mutation of miRNA target-seed sequences within the
3UTR regions of specific targets, as has been done for AID
(47, 48), will provide the strongest argument for relevance.
As both miR-155 and SHIP1 regulate critical and overlapping
functions of a variety of cell types of the immune system,
therapeutic manipulation of this molecular interaction may
prove to be useful in the treatment of diverse pathological
conditions, including infection, cancer, and autoimmunity.
Materials and Methods
Cell Culture. Raw 264.7 macrophage and 293T cells were cultured in complete
DMEM with 10% FBS, 100 units/ml penicillin, 100 units/ml streptomycin. For
generation of BMMs, bone marrow cells were isolated from the tibias and
femurs of mice as previously described (19). All cells were cultured in a
humidified incubator with 5% CO2 at 37 °C. Primary macrophages were
stimulated using fresh DMEM containing 10 ng/ml 055-B5 LPS (Sigma), while
Raw 264.7 cells were treated with LPS at 200 ng/ml.
Sequence Alignments. SHIP1 3UTR sequences from human, mouse, rat and
dog were obtained and aligned with each other and with the miR-155 seed
region using TargetScan (24).
DNAConstructs.Retroviral constructsMGandMG-155 (human sequence)were
described previously (19). Oligonucleotide sequences used to generate new
constructs are provided as supplemental data [supporting information (SI)
Table S1]. The MGP-155 expression cassette containing the mouse miR-155
hairpin sequence and flanking regions was cloned from cDNA made from
LPS-treated BMMs. The cassette was subcloned into MGP. MGP is a modified
pMSCVvector (Clontech)whereGFPwasplaceddownstreamof the5 LTR, and
the miR-155 expression cassette was cloned downstream of the GFP stop
codon (detailed cloning strategy available upon request). The h155, h155mut,
and siSHIP1 oligonucleotides, which producemature humanmiR-155, human
miR-155 seed mutant, and siRNA against mouse SHIP1, respectively, were
designed using the Invitrogen Block-iT pol II miR RNAi strategy and PCR
amplified using Fw NotI- and Rev XhoI- containing primers. The Invitrogen
Block-iT RNAi Designerwas used to predict the siRNA sequence againstmouse
SHIP1. For reporter assays, thePicalm3UTRwas clonedasdescribedpreviously
(7). The mouse SHIP1 3UTR was amplified by PCR from cDNA derived from
mouseRAW264.7 cells. This PCRproductwas cloned intopmiReport (Ambion)
using SpeI and HindIII. Assembly PCR was used to mutate the 6-nucleotide
miR-155 seed region. A 2-mer control insert and the IRAK1 3UTR (used as
negative control) were described previously (7).
Luciferase-Beta Gal Reporter Assays. Experiments were performed as previ-
ously described using FUW, FUW-155, -gal expression vector, and pmiRe-
port vectors transfected into 293T cells (7). Transfections were carried out
with TransIT 293 (Mirus). Data were normalized for transfection efficiency
using a -gal reporter and is represented as the ratio of luciferase activity
of the transfection containing FUW-155 to that of the transfection con-
taining FUW.
RAW 264.7 Stable Cell Lines. To generate VSV-G-pseudotyped MSCV retrovi-
ruses, 2  106 293T cells were transfected with pGag-Pol, pVSV-G, and either
MGP,MGP-h155,MGP-h155mut, orMGP-siSHIP1. Transfectionwasperformed
with TransIT 293 as per manufacturer’s instructions. After 48 h, viral superna-
tant was harvested and used to infect 5  105 RAW 264.7 cells for 8 h in the
presence of polybrene at 10 g/ml. After 48 h, stably transduced cells were
selected using puromycin at 10 g/ml for 7 to 10 days.
Mice.Wtmice on a C57BL/6 genetic background were bred and housed in the
Caltech Office of Laboratory Animal Resources facility. Mice deficient in
miR-155 and on a C57BL/6 genetic background were obtained from Alan
Bradley at the Wellcome Trust Sanger Institute, Cambridge, U.K. All experi-
ments were approved by the Caltech Institutional Animal Care and Use
Committee.
Bone Marrow Reconstitution. Experiments were performed as previously de-
scribed (7), with the followingmodifications: HSC-enriched bonemarrowwas
cultured for 48 h before the first spin infection using the respective retroviral
vector. Transfection of retroviral constructs was performed using TransIT 293.
Cells were subjected to 2 spin infections, and transduced cells were delivered
to recipient mice through retro-orbital injection.
RNA Quantification. SYBR Green-based quantitative real-time PCR was con-
ducted using the 7300 Real-time PCR system (Applied Biosystems) to assay BIC,
miR-155, 5s, SHIP1 mRNA ,and L32 mRNA levels as described previously (7).
Mature miR-155 and 5s RNA were assayed using a mirVana miRNA detection
kit as per manufacturer’s instructions (Ambion). Mouse BIC, SHIP1, and L32
mRNA were detected using specific primers (see Table S1). Northern blotting
was performed as described (19) using a probe reverse complementary to the
human miR-155 seed mutant (see Table S1).
Western Blotting. Cell extracts were size-fractionated by SDS/PAGE and trans-
ferred to a nitrocellulose membrane using a semidry transfer apparatus
(Bio-Rad). Western blotting was performed using the following antibodies:
SHIP1 V-19 (sc-1963), SHIP1 M-14 (sc-1964), -Tubulin B-7 (sc-5286), donkey
anti-goat HRP-conjugated (sc-2020), goat anti-rabbit HRP-conjugated (sc-
2004), goat anti-mouseHRP-conjugated (sc-2005) (Santa Cruz Biotechnology);
-Actin (A2066), -Actin (A1978) (Sigma); SHIP1 (D1163), Akt1 (C73H10),
Phospho-AKT (Ser-473) (Cell Signaling). Protein-expression intensities were
determined using Scion Image software.
Flow Cytometry. Fluorophore-conjugated monoclonal antibodies specific to
CD11b (Mac1), Ter-119, or B220 (eBioscience) were used to stain RBC-lysed
splenocytes and RBC-containing bone marrow cells that were washed and
fixedwith paraformaldehyde (1%final). Stained cellswere assayedusing aBD
FACSCalibur flow cytometer (BD) and further analyzedwith FlowJo software.
Morphological Assessment of Hematolymphoid Tissues. Histological and cyto-
logical samples were prepared and analyzed as described previously (7).
Statistical Tests. All statistical tests were performed using Microsoft Excel.
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